Statistical evaluation of worst-case robust optimization intensity-modulated proton therapy plans using an exhaustive sampling approach

Zhiyong Yang1,2, Heng Li2, Yupeng Li2, Yuting Li2, Yu Chang1, Qin Li1, Kunyu Yang1, Gang Wu1, Narayan Sahoo2, Falk Poenisch2, Michael Gillin2, X. Ronald Zhu2 and Xiaodong Zhang2*

Abstract

Purpose: To assess the worst-case robust optimization IMPT plans with setup and range uncertainties and to test the hypothesis that the worst-case robust optimization strategies could cover most possible setup and range uncertainties in the real scenarios.

Methods: We analyzed the nominal and worst-case robust optimization IMPT plans of seven patients with head and neck cancer patients. To take uncertainties into account for the dose calculation, we performed a comprehensive simulation in which the dose was recalculated 625 times per given plan using Gaussian systematic setup and proton range uncertainties. Subsequently, based on the simulation results, we calculated the target coverage in all perturbation scenarios, as well as the ratios of target coverage located within the threshold of eight worst-case scenarios. We set the criteria for the optimized plan to be the ratios of 1) the dose delivered to 95% (D95%) of clinical target volumes 1 and 2 (CTV1 and CTV2) above 95% of the prescribed dose, and 2) the D95% of clinical target volume 3 (CTV3) above 90% of the prescribed dose in worst-case situations.

Results: The probability that the perturbed-dose indices of the CTVs in each scenario were within the worst-case scenario limits ranged from 89.51 to 91.22% for both the nominal and worst-case robust optimization IMPT plans. A quartile analysis showed that the selective robust optimization IMPT plans all had higher D95% values for CTV1, CTV2, and CTV3 than did the nominal IMPT plans.

Conclusions: The worst-case strategy for robust optimization is adequately models and covers most of the setup and range uncertainties for the IMPT treatment of head and neck patients in our center.

Keywords: Intensity-modulated proton therapy, Robust optimization, Worst-case scenarios, Proton dose uncertainties

Introduction

In intensity-modulated proton therapy (IMPT), setup and range uncertainties can prevent scanning spots from matching properly to form a conformal dose distribution [1, 2]. To account for these uncertainties, robust IMPT plans can be constructed using worst-case robust optimization, which is now implemented in the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, CA) [3]. The so-called worst-case strategy optimizes the minimum and maximum doses at each voxel with different setup and range uncertainties to keep the plan robustness [4–6]. This method is fast and convenient because only a limited number of perturbation scenarios need to be calculated. It has been used both as a strategy to implement uncertainties in the plan’s robustness-optimization process and as a tool to evaluate the robustness of the nominal plan [4, 7].
In the worst-case robust optimization, dose perturbations are usually performed by calculating the plan for eight worst-case perturbation scenarios (two scenarios for range uncertainties of ±3.5% and six for setup uncertainties of ±3 mm in the left-right (L-R), superior-inferior (S-I), and anterior-posterior (A-P) directions). In our center, these eight worst-case settings are gradually introduced into the clinical routine for the robust optimization [7, 8].

In some situations, the perturbation settings may be conflicted or insufficient. For example, the perturbation settings may comprise sometimes, for instance, the error on a perturbation direction, cannot be +3 mm and −3 mm at the same time; conversely, the perturbation settings may miss some scenarios, since setup uncertainties may happen in all directions simultaneously with range uncertainties [9, 10].

Several previous studies have used simulations to estimate and verify the robustness of proton plans. Casiraghi et al. simulated 14 and 85 perturbation scenarios for a nominal IMPT plan by using the dose-error-bar distribution algorithm and the Monte Carlo approach to evaluate the feasibility of applying the worst-case scenarios approach to estimate the plan robustness [7]. Lowe et al. also applied the dose-error-bar distribution algorithm to incorporate the effect of fractionation in the evaluation of IMPT plan robustness with regard to setup errors [11, 12]. Park et al. used the fast-proton-dose calculation algorithm and statistical analysis method to assess the effect of setup errors and range uncertainties on proton dose distributions and dose–volume histograms (DVHs) [13]. Van Der Voort et al. simulated the perturbation values for the scenarios to be included in robust optimizations and calculated the perturbation values to ensure adequate clinical target volume (CTV) coverage for fractionated IMPT treatments in the presence of prior known systematic and random setup errors and range error distributions [10]. However, it is still unknown whether the robust optimization settings of eight worst-case perturbation scenarios are adequate for the development of a robust IMPT plan covering most possible setup and range uncertainties.

Accordingly, in this study, we have two research objectives: First, we tested the plan robustness of the nominal and worst-case robust optimization IMPT plans by calculating all possible dose distributions of 625 perturbation scenarios; Second, we evaluated whether the robustness optimization settings of eight worst-case perturbation scenarios which represent the largest deviations of uncertainties are sufficient to cover all possible dose distributions by comparing the target coverage of 625 perturbation scenarios with that of eight worst-case scenarios. In order to simulate all possible perturbation scenarios, we use the Gaussian sampling function to simulate a large number of the systemic setup and range uncertainties. We calculated the perturbation dose of both the nominal IMPT plan and worst-case robust optimization plan using the fast proton dose calculation algorithm proposed by Park et al. [14], then compared the dose deviations obtained from the simulations between these two plans.

Materials and methods
Patient selection and treatment planning
We retrospectively evaluated the clinically approved, multi-field optimization IMPT plans of seven patients with head and neck (HN) cancers. Patient and target characteristics are shown in Additional file 1: Table S1. To control the impact of planning target volume (PTV) margin on the dose coverage, the treatment plans were re-optimized by a single planner using the CTV directly. The treatment plans were re-optimized with three beam angles (60°, 180°, and 300°) using the selective robust optimization algorithm, which was an altered worst-case robust optimization algorithm implemented in Eclipse version 13.7, as detailed in our previous research [3]. The prescription dose for all plans was 70 Gy relative biological effectiveness (RBE) to CTV1 (defined as gross disease plus a 1-cm margin) in 33 fractions; 63 Gy RBE to CTV2 (encompassing the high-risk nodal volume adjacent to gross disease in the neck) in 33 fractions; and 57 Gy RBE to CTV3 (encompassing an additional margin beyond CTV2 for patients with pharyngeal tumors and uninvolved nodes in the neck considered at risk of harboring subclinical disease) in 33 fractions [15]. The objective function of the CTV was computed for the worst-case situations, including setup uncertainties of ±3 mm and range uncertainties of ±3.5%. After re-optimization, the selective robust optimization IMPT plans were then evaluated for the worst-case situations to keep the D99% of CTV1 and CTV2 above 95% of the prescribed dose, and the D95% of CTV3 above 90% of the prescribed dose. The reduction of the dose requirement for CTV3 was made because of the difficulty of robust optimization in patients with bilateral CTVs [10] and the need to spare critical organs while sufficiently covering the targets. After the selective robust optimization, the same objective functions for CTVs and organs at risk (OARs) were used to optimize the nominal plan, excluding the range uncertainties of ±3.5% and setup uncertainties of ±3 mm. After optimization, all 14 plans were normalized to facilitate dose comparisons. The normalization point—CTV1 D98% of 70 Gy, where Dx% was defined as the lowest dose covering x% of the volume—was the same for both the nominal and the selective robust optimization plans. The D98% of CTVs, D1% of spinal cord and brain stem, and Dmean of the left and right parotids were recorded and reported.
Simulation and calculation of perturbation scenarios

Our goal was to exhaustively investigate all possible dose distributions for the perturbation scenarios. We used the Gaussian distribution function to simulate the systematic setup and range uncertainties, which influenced the dose calculation for all fractions. All sampling uncertainties were assumed to be independent. The perturbation scenarios are created by sampling the setup and range uncertainties in all four freedoms simultaneously. The setup uncertainties were randomly drawn from the Gaussian distribution function, with the mean at the planning isocenter; the standard deviation was equal to 1.5 mm in the L-R, S-I, and A-P directions to simulate the systematic setup uncertainties. Range uncertainties were also drawn from the Gaussian distribution function, with the standard deviation equal to 1.75% of the nominal computed tomography (CT) number-to-stopping power ratio calibration curve. Hence, about 5% of the total perturbation scenarios were outside the setup uncertainties (from –3 mm to 3 mm) and range uncertainties (from –3.5 to 3.5%) of the worst-case scenarios. The sampling number for the Gaussian simulation perturbation scenarios was set at 625.

Even if the simulation counts are limited to 625 dose calculations per plan, calculation of doses with the treatment planning system is still time-consuming. Therefore, in this study, dose distributions were approximated using a fast dose calculation method [14]. This method approximated new proton doses from the pre-computed nominal dose distributions by taking into account the perturbation of the radiologic path length caused by an isocenter shift or range uncertainties. The perturbed dose was calculated for each scenario and DVHs were obtained. Dose-volume indices including the D95% of the CTVs, D1% of the brain stem and spinal cord, and Dmean of the left and right parotids, were also recorded.

Statistical analysis

SPSS 24.0 software (IBM, Armonk, NY) was used for statistical analysis. P values of less than 0.05 were considered statistically significant. The DVHs of the nominal IMPT and selective robust optimization IMPT plans were compared using a two-sided Wilcoxon signed-rank test to examine the dose indices of targets and OARs.

Comparison of target coverage for eight worst-case scenarios and 625 perturbation scenarios

We used the lowest D95% value among the CTVs of the eight worst-case scenarios (including range uncertainties of ±3.5% and setup uncertainties of ±3 mm for 3 directions) for a certain nominal plan as a threshold to determine whether the target coverages for each of the perturbation scenarios were bound within the worst-case robust scenarios. The probabilities that the D95% values of the CTVs of the 625 perturbation scenarios were higher than the threshold were calculated to investigate whether the ratio of that the worst-case robust strategy could ensure adequate coverage of the target volume for all perturbation scenarios.

Comparison of target coverage in the 625 perturbation scenarios and the 95% of the prescribed dose

We calculated the D95% of CTV1, CTV2, and CTV3, as target coverage in our study. The ratio of the D95% above 95% of the prescribed dose in all 625 perturbation scenarios was also calculated. To evaluate the plan robustness, we also calculated the medians and interquartile ranges of the D95% of CTV1, CTV2, and CTV3 for 625 perturbation scenarios. The differences in target coverage between the nominal and selective robust optimization IMPT plans were also compared using a two-sided Wilcoxon signed-rank test.

Results

A total of 4375 dose distributions from 7 patients were calculated and analyzed in this study. In order to present our results in a simple and clear way, we selected case #5, which had the largest CTV1 volume, as a representative case for demonstration.

Table 1 shows that, in this case, the D98% values for CTV1, CTV2, and CTV3 were not significantly different between the selective robust optimization IMPT plan and the nominal IMPT plan. However, the D1% of spinal cord (42.86 Gy) and brain stem (45.36 Gy) in the selective robust optimization IMPT plans were significantly higher than that of the nominal IMPT plan (40.26 Gy, \( P = 0.028 \)) and 43.82 Gy, \( P = 0.028 \)).

Comparison of target coverage among eight worst-case scenarios and 625 perturbation scenarios

Table 2 shows the probabilities that the dose indices of 625 perturbation scenarios were within the threshold of the eight worst-case scenarios in terms of target volumes/OARs. The comparisons of the thresholds of the eight worst-case scenarios show that the target coverages of CTV1 and CTV2 were significantly higher in the selective robust optimization IMPT plans (68.71 Gy, and 61.86 Gy, respectively) than in the nominal IMPT plans (67.51 Gy, \( P = 0.018 \); and 60.88 Gy, \( P = 0.018 \)). For the 625 perturbation scenarios, the probabilities of the D95% of CTV1 being above the threshold were 90.38% in the selective robust optimization IMPT plans and 91.22% in the nominal IMPT plans. The probabilities of the D95% of CTV2 being above the threshold were 90.63% in the selective robust optimization IMPT plans and 89.51% in the nominal IMPT plans. The probabilities of D95% of CTV3 being above the threshold were 90.63% in the selective robust optimization IMPT plans and 90.13% in
the nominal IMPT plans. For OARs (spinal cord, brain stem, and left and right parotids), at least 94.86% of the 625 perturbation scenarios showed lower dose indices than those given by the maximum value of the eight worst-case scenarios.

The confidence intervals for clinical target volume coverage in the 625 perturbation scenarios and eight worst-case scenarios are shown in Fig. 1. For CTV1 and CTV2, the eight worst-case scenario thresholds for the selective robust optimization and the normal IMPT plans were similarly located within the 95% confidence interval range. For CTV3, the eight worst-case scenario thresholds for the selective robust optimization and the normal IMPT plans were similarly located within the 90% confidence interval range. These results suggest that the thresholds sufficiently evaluated the plan robustness for both the nominal and the robust optimization IMPT plans. The dose deviation maps of targets for case 5—the representative case—are shown in Fig. 2. The dose deviations were scaled to a color band and marked by different range uncertainty levels, located in the setup uncertainties coordinates. For all three CTVs for case 5, the selective robust optimization IMPT plan showed fewer cold scenarios than did the nominal plan.

### Comparison of target coverage of 625 perturbation scenarios and the 95% of the prescribed dose
For all three CTVs evaluated, the ratios of the D95% of the CTV to 95% of the prescribed dose were significantly higher in the selective robust optimization plan than in the nominal plan (P = 0.043 for CTV1, 0.027 for CTV2, and 0.028 for CTV3), as shown in Table 3. The median values of D95% for CTV1, CTV2, and CTV3 of the selective robust optimization IMPT plans were 69.92 Gy, 63.60 Gy, and 55.10 Gy. The median values of D95% for CTV1, CTV2 and CTV3 of the selective robust optimization IMPT plans were 69.24 Gy, 62.75 Gy, and 54.43 Gy. The median values of D95% for CTV1, CTV2 and CTV3 of the selective robust optimization IMPT plans were significantly higher than those of the nominal IMPT plans (P = 0.018, 0.018, and 0.028). For CTV1, the interquartile range of D95% of the selective robust optimization IMPT plans was smaller than that of the nominal IMPT plans (P = 0.018); there was no significant difference in

### Table 1 Summary of doses to targets and OARs

| Parameter                | Robust optimization IMPT Mean (SD) | Nominal IMPT Mean (SD) | P^a |
|--------------------------|-----------------------------------|------------------------|-----|
| CTV1, D98% (Gy)         | 70.00 (0.00)                      | 70.00 (0.00)           | 1.000 |
| CTV2, D98% (Gy)         | 64.66 (1.27)                      | 64.46 (1.57)           | 0.735 |
| CTV3, D98% (Gy)         | 57.47 (0.72)                      | 57.53 (1.05)           | 0.866 |
| Spinal cord, D1% (Gy)   | 42.86 (2.88)                      | 40.26 (3.63)           | 0.028^* |
| Brain stem, D1% (Gy)    | 45.36 (8.82)                      | 43.82 (9.41)           | 0.028^* |
| Left parotid, Dmean (Gy)| 37.13 (3.98)                      | 36.00 (5.00)           | 0.398 |
| Right parotid, Dmean (Gy)| 37.46 (6.60)                      | 36.72 (5.96)           | 0.310 |

*Abbreviations: CTV clinical target volume, Dx% dose delivered to x% of the volume, Dmax the maximum dose delivered to the structure, Dmean the average dose delivered to the structure.

*Comparison of the selective robust optimization IMPT plan and the nominal IMPT plan.*

### Table 2 Statistical summary of the probabilities that the perturbed dose indices of 625 scenarios were within the worst-case scenarios

| Parameter                | The threshold of eight worst-case scenarios (Gy) | The probabilities of Gaussian simulation within the eight worst-case scenarios |
|--------------------------|-----------------------------------------------|------------------------------------------------------------------------------|
|                          | Selective robust IMPT Mean (SD) | Nominal IMPT Mean (SD) | P^a           | Selective robust IMPT Mean (SD) | Nominal IMPT Mean (SD) |
| CTV1, D98%               | 68.71 (0.49)                       | 67.51 (0.85)                       | 0.018^* 90.38% (2.53%) | 90.22% (2.05%) |
| CTV2, D98%               | 61.86 (1.49)                       | 60.88 (1.44)                       | 0.018^* 90.63% (2.59%) | 89.51% (4.47%) |
| CTV3, D98%               | 51.98 (3.27)                       | 51.34 (3.18)                       | 0.063 90.63% (3.78%) | 90.13% (4.10%) |
| Spinal cord, D1%         | 48.07 (4.29)                       | 47.19 (5.14)                       | 0.398 96.01% (1.63%) | 95.93% (1.96%) |
| Brain stem, D1%          | 50.84 (8.46)                       | 49.92 (10.83)                      | 0.398 97.01% (1.21%) | 95.87% (1.54%) |
| Left parotid, Dmean      | 40.22 (3.82)                       | 39.14 (5.38)                       | 0.398 95.68% (2.94%) | 95.34% (2.50%) |
| Right parotid, Dmean     | 40.63 (6.04)                       | 40.61 (5.52)                       | 1.000 94.86% (1.85%) | 94.80% (2.00%) |

*Abbreviations: CTV clinical target volume, Dmax the maximum dose delivered to the structure, Dmean the average dose delivered to the structure.

*P values < 0.05 were considered statistically significant.

*Comparison of the threshold of eight worst-case scenarios between the selective robust optimization IMPT plan and the nominal IMPT plan.*
Fig. 1 Boxplots for the selective robust and nominal plans show the confidence intervals of target coverage of 625 perturbation scenarios were shown for all seven cases. Sections a is CTV1, sections b is CTV2, and Sections c is CTV3.

Fig. 2 Dose deviation maps of targets for case 5. The dose deviations of CTV D95% values between the nominal scenario and each perturbation scenarios are shown in the 3D setup error spaces [x direction, LR (left-right); y direction, SI (superior-inferior); z direction, AP (anterior-posterior)]. The dose deviations are scaled to the color bands (from -6Gy to 2Gy) and marked by different range uncertainty levels, located in the setup error coordinates. For all three CTVs of case 5, the selective robust optimization IMPT plan (a, c, e) shows fewer cold scenarios than the nominal plan (b, d, f).
The robustness evaluation criteria were D 95% of the eight worst-case scenarios before the treatment be-
evaluate the plan robustness of the HN IMPT plans with

Discussion
In our center, we use the eight worst-case scenarios to
evaluate the plan robustness of the HN IMPT plans with
the eight worst-case scenarios before the treatment be-

interquartile ranges for CTV2 and CTV3. The probabil-
distributions of the D95% values for all CTVs in case
5 are shown in Fig. 3, the CTVs D95% values of the se-
selective robust optimization IMPT plans domain in
higher dose area than that of the nominal plans.

Table 3 Ratio and quartile analysis of Gaussian simulations

| CTV | Ratioa | Median (Gy) | Interquartile range (Gy) | P
|------|---------|-------------|-------------------------|---
| CTV1 D95% | 96.96% (6.49%) | 69.92 (0.35) | 1.02 (0.33) | 0.043
| CTV2 D95% | 96.11% (8.57%) | 63.60 (1.49) | 1.49 (0.50) | 0.027
| CTV3 D95% | 84.55% (14.64%) | 55.10 (1.61) | 2.20 (1.23) | 0.499

Abbreviations: CTV clinical target volume, Dx dose delivered to x% of the volume
*P values < 0.05 were considered statistically significant
*aRatio above 95% of the prescribed dose
*bComparison of the selective robust optimization IMPT plan and the nominal IMPT plan

doctrine of eight worst-case scenarios, as shown in Table 2. In a
previous study, van Herk et al. [16, 17] considered a cum-
ulative minimum CTV dose of 95% of the prescribed
dose above 90% of the patient population to be an ade-
quate for photon CTV-PTV margin. Our result shows a
similar probability of the patient population for the
CTV coverage of the threshold of eight worst-case sce-
narios. Unlike van Herk et al., who developed their sim-
ulations using ideal synthetic photon dose distributions
that were not sensitive to real patient setup uncertain-
ties, we calculated realistic proton dose distributions
for both setup and range uncertainties using the fast-pro-
ton-dose calculation algorithm. Therefore, it was cre-
ducible to apply the eight worst-case scenarios as a tool
to evaluate the plan robustness of the nominal and robust
optimization plans to the setup and range uncertainties
in the IMPT treatment.

The robust optimization plans kept CTV1 and CTV2
coverage above 95% of the prescribed dose for 96.11 to
96.96% of the perturbation scenarios, as shown in Table
3. The target coverage for CTV1 and CTV2 also
achieved the margin assumption of van Herk et al. [16,
17]. However, the coverage of CTV3 dropped approxi-
mately to 84.55%, across the patient group and in both
the selective robust optimization and nominal IMPT
plans. This reduction of CTV3 was expected, since the
robustness evaluation setting for CTV3 was D95% above
90% of the prescribed dose; in contrast, comparing to
CTV1 and CTV2, dropped from 95 to 90% of the pre-
scribed dose. This difference may be the result of the
large anatomical changes of CTV3 in the lower neck, as
mentioned in previous studies; for example, in a study
by Van Der Voort et al., bilateral HN patients need a
higher-range robust setting to cover the same degree of
range uncertainties for their CTV-low volume (similar
to CTV3 in our study) [10]. Sometimes, CTV1 and
CTV2 are in the volume of the CTV3, but the CTV3 is
adjunct to the OARs (such as spinal cord or parotids),
and the dose gradient beyond CTV3 may be much
higher than that beyond CTV1 and CTV2 [18]. This
situation leads the target coverage of CTV3 to be less
robust than that of CTV1 and CTV2 in our study could
only keep 84.55% probability of target coverage above
the threshold of the eight worst-case scenarios. This
finding suggests that robustness settings need to be se-
parately considered for various treatment sites due to the
target shapes and anatomical changes.

In our center, nominal HN IMPT plans are still used
in clinical practice, but we needed to confirm the plan
robustness of the nominal HN IMPT plans using the
eight worst-case scenarios before the treatment. In this
study, we found that, if the nominal IMPT plans could
satisfy the robust criteria (the D95% of CTV1 and CTV2
above 95% of the prescribed dose, and the D95% of
CTV3 above 90% of the prescribed dose in the eight worst-case thresholds), 90% of all 625 scenarios of the target coverage of CTVs would be above the worst-case thresholds. These results suggest that the plan robustness of the nominal HN IMPT plans could still be retained above the eight worst-case thresholds for 90% of the patient population. This may be the result of the large spot size of the scanning system in our center (1σ, as measured in air at the isocenter: approximately 5 mm at the highest energy level and 10 mm at the lowest energy level when the energy absorber is used or approximately 14.5 mm without the use of the energy absorber) [19]. The large spot size may blur and reduce the sensitivity of the dose distribution to the uncertainties [20, 21].

One of the limitations of this study was that we did not apply robust optimization on OARs (e.g., the spinal cord and brain stem). In theory, the selective robust optimization methods can optimize the targets and OARs together under setup and range uncertainties. However, for HN cases, this may lead to some conflicts of the robust optimization objectives, since the OARs are usually adjacent to, or even overlapped with, the targets (e.g., parotids) [15]. Hence, our study was focused on the influence of worst-case robust optimization to targets and to set the selective robust optimization objectives only on targets. Second, we did not divide the setup uncertainties into system and random errors separately and only used the Gaussian sampling to simulate the systematic setup and range uncertainties directly.

---

**Fig. 3** The probability distributions of D95% values for Gaussian simulation strategies for CTV1 (a), CTV2 (b), and CTV3 (c) are shown for case #5. The probability distributions of the selective robust optimization IMPT plans (red bars) are seen in a higher dose area than that of the nominal plans (green bars). The thresholds of the eight worst-case scenarios for the selective robust optimization (pink dashed line) and nominal (pink solid line) IMPT plans are also shown.
The systematic setup and range uncertainties influenced our dose calculation for all fractions. We did this because we are focusing on verifying the hypothesis that the dose distributions recalculated for the realization of the largest setup and range uncertainties could represent the largest deviations of the delivered dose from the nominal plan dose. Hence, we only simulated the systematic setup uncertainties that would be dominant and would impact the dose calculation of all fractions [13, 16, 17]. The random setup uncertainties might be obscured and averaged during the treatment fractions, they would have less influence on the target coverage than the systematic setup uncertainties [13]. Additionally, it is important to note that the results presented in this work may be affected by the dose calculation accuracy. Based on the previous study, the RMS of the difference in relative dose between the fast range-corrected proton dose approximate algorithm and the full 3D pencil beam convolution superposition algorithm of Eclipse TPS should be less than 1–2% [14, 22]. This accuracy of the DVH curve might still be clinically acceptable.

Conclusion
In this study, we evaluated the assumption that the eight worst-case scenarios for robust optimization could retain the target coverage for systematic setup and range uncertainties. We found that the worst-case robust evaluation strategy is adequate to model the target coverage for possible setup and range uncertainties in both the nominal and robust optimization plans for HN patients in our center. Compared to the higher target volumes, CTV1 and CTV2, CTV in the neck, CTV3, may be less robust for IMPT and may lose some target coverage. This finding suggests that robustness settings need to be separately considered for the various treatment sites and that, our results may be appropriate only for HN patients. Further studies on various treatment sites are needed.

Additional file

Additional file 1: Table S1. Patient and target characteristics. (DOCX 15 kb)

Abbreviations
CTV1: Clinical target volume 1; CTV2: Clinical target volume 2; CTV3: Clinical target volume 3; DVH: Dose–volume histograms; Dv%x: The lowest dose covering x% of the volume; HN: Head and neck; IMPT: Intensity-modulated proton therapy; OAR: Organ at risk; PTV: Planning target volume 2

Acknowledgments
We thank Laura Russell from Department of Scientific Publications of MD Anderson for editing the manuscript. This work is supported by the National Natural Science Foundation of China (Grant No.81803047) (ZY) and by the NIH Cancer Center Support Grant (CCSG) (XZ).

Authors’ contributions
ZY, Yupi, and YuLi developed most of the fast-proton-dose calculation tool and performed all the calculation. XZ and HL helped to conceive of the study and participated in the simulation design. NS, FP, MG, XRZ, YC, QL, KY and GW participated in the research design and helped to draft the manuscript. All authors read and approved the final manuscript.

Funding
1) National Natural Science Foundation of China (Grant No.81803047)
2) NIH Cancer Center Support Grant (CCSG)

Availability of data and materials
Please contact author for data requests.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. 2. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1150, Houston, TX 77030, USA.

Received: 13 December 2018 Accepted: 11 July 2019
Published online: 19 July 2019

References
1. Graeff C, Durante M, Bert C. Motion mitigation in intensity modulated particle therapy by internal target volumes covering range changes. Med Phys. 2012;39:6004–13.
2. Malyapa R, Lowe M, Bolsi A, Lomax AJ, Weber DC, Albertini F. Evaluation of robustness to setup and range uncertainties for head and neck patients treated with pencil beam scanning proton therapy. Int J Radiat Oncol Biol Phys. 2016;95:154–62.
3. Li Y, Niemela P, Liao L, Jiang S, Li H, Poenisch F, et al. Selective robust optimization: a new intensity-modulated proton therapy optimization strategy. Med Phys. 2015;42:8460–7.
4. Pflugfelder D, Wilsens J, Delffe U. Worst case optimization: a method to account for uncertainties in the optimization of intensity modulated proton therapy. Phys Med Biol. 2008;53:1689.
5. Fredriksson A, Forsgren A, Hårdemark B. Minimax optimization for handling range and setup uncertainties in proton therapy. Med Phys. 2011;38:1672–84.
6. Lomax AJ, Pedroni E, Rutz HP, Goitein G. The clinical potential of intensity modulated proton therapy. Z Med Phys. 2004;14:47–52.
7. Casiraghi M, Albertini F, Lomax A. Advantages and limitations of the ‘worst case scenario/approach in IMPT treatment planning. Phys Med Biol. 2013;58:1323.
8. Liu W, Zhang X, Li Y, Mohan R. Robust optimization of intensity modulated proton therapy. Med Phys. 2012;39:1079–91.
9. Fredriksson A, Bokrantz R. A critical evaluation of worst case optimization methods for robust intensity-modulated proton therapy planning. Med Phys. 2014;41:081701.
10. Van Der Voort S, van de Water S, Perkó Z, Heijmen B, Lathouwers D, Hoogeman M. Robustness recipes for minimax robust optimization in intensity modulated proton therapy for oropharyngeal cancer patients. Int J Radiat Oncol Biol Phys. 2016;95:536–45.
11. Lowe M, Albertini F, Attkenhead A, Lomax AJ, MacKay R. Incorporating the effect of fractionation in the evaluation of proton plan robustness to setup errors. Phys Med Biol. 2015;61:413.
12. Lowe M, Attkenhead A, Albertini F, Lomax AJ, MacKay R. A robust optimization approach accounting for the effect of fractionation on setup uncertainties. Phys Med Biol. 2017;62:8178.
13. Park PC, Cheung JP, Zhu XR, Lee AK, Sahoo N, Tucker SL, et al. Statistical assessment of proton treatment plans under setup and range uncertainties. Int J Radiat Oncol Biol Phys. 2013;86:1007–13.

14. Park PC, Cheung J, Zhu XR, Sahoo N, Dong L. Fast range-corrected proton dose approximation method using prior dose distribution. Phys Med Biol. 2012;57:3555.

15. Frank SJ, Cox JD, Gillin M, Mohan R, Garden AS, Rosenthal DI, et al. Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice. Int J Radiat Oncol Biol Phys. 2014;89:846–53.

16. Van Herk M, Remeijer P, Rasch C, Lebesque JV. The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:1121–35.

17. Van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol. 2004;14:52–64.

18. Van de Water S, van Dam I, Schaart DR, Al-Mamgani A, Heijmen BJ, Hoogeman MS. The price of robustness: impact of worst-case optimization on organ-at-risk dose and complication probability in intensity-modulated proton therapy for oropharyngeal cancer patients. Radiother Oncol. 2016;120:62.

19. Smith A, Gillin M, Bues M, Zhu XR, Suzuki K, Mohan R, et al. The M. D. Anderson proton therapy system. Med Phys. 2009;36:4068–83.

20. Dowdell S, Grassberger C, Sharp G, Paganetti H. Interplay effects in proton scanning for lung: a 4D Monte Carlo study assessing the impact of tumor and beam delivery parameters. Phys Med Biol. 2013;58:4137.

21. Grassberger C, Dowdell S, Lomax A, Sharp G, Shackelford J, Choi N, et al. Motion interplay as a function of patient parameters and spot size in spot scanning proton therapy for lung cancer. Int J Radiat Oncol Biol Phys. 2013;86:380–6.

22. Arjomandy B, Sahoo N, Ciangaru G, Zhu R, Song X, Gillin M. Verification of patient-specific dose distributions in proton therapy using a commercial two-dimensional ion chamber array. Med Phys. 2010;37:3831–7.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.